The Role of Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia (CLL) and the Achievement of Minimal Residual Disease Negativity in Relapsed Refractory CLL. Hematol Meeting Rep 2009, 1 (2). https://doi.org/10.4081/hmr.v1i2.226.